Elevance Health Inc. Common Stock vs Novo Nordisk A/S — how do they compare? Elevance Health Inc. Common Stock trades at $401.8 (market cap $86.95B), while Novo Nordisk A/S trades at $38.26 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals.
| ELV | NVO | |
|---|---|---|
Market Cap | $86.95B | $165.31B |
Volume | 782,706 | 11,432,838 |
Sector | Health | Health |
52-Week High | $426.79 | $63.98 |
52-Week Low | $280.74 | $35.29 |
Enterprise Value | $107.76B | $179.56B |
Dividend Yield | 1.72% | 4.71% |
Typical Hold Time | — | 116 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Elevance Health provides health plans and healthcare services. Its offerings include medical, behavioral health, pharmacy, dental, vision, and complex-care solutions, including through the Carelon business.
Read more on ELV →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →